Background: The present study reports on the efficacy and safety of adjuvant docetaxel in real-life patients with early-stage breast cancer. Methods: This is a prospective, multicenter, post-marketing study that evaluates the efficacy and safety of docetaxel-based regimens in patients with early breast cancer treated between 2007 and 2012. Results: A total of 698 female breast cancer patients receiving adjuvant docetaxel-based regimens were included in this study. Docetaxel monotherapy was administered in 4.2%, whilst most patients received polychemotherapy. Non-hematological adverse events included skin reactions in 32.7% of the subjects. Multiple adverse events were reported and most commonly included asthenia (66.5%), alopecia (43.4%), and diarrhea (24.2%). It is noteworthy that no fatal toxicities occurred. Several hematological adverse events were reported during treatment, with anemia being the most common. Conclusion: The results of this real-life experience, characterized by a relatively large sample size and long follow-up, confirm that docetaxel is effective and well tolerated in early-stage breast cancer patients.

Keywords:
Docetaxel, Breast cancer, Adverse events, Safety, Toxicity
1.
Bissery MC, Nohynek G, Sanderink GJ, Lavelle F: Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 1995;6:339-355, 363-368.
2.
Pant S, Chilukuri MP, Ramaswamy B: Docetaxel for the post-surgery treatment of patients with node-positive breast cancer. Ther Clin Risk Manag 2008;4:419-424.
3.
Martin M, Pienkowski T, Mackey J, et al.; Breast Cancer International Research Group 001 Investigators: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-2313.
4.
Azim HA, Abdal-Kader YSED, Mousa MM, Malek RA, Abdalmassih MK, Ibrahim NY: Taxane-based regimens as adjuvant treatment for breast cancer: a retrospective study in Egyptian cancer patients. Asian Pac J Cancer Prev 2015;16:65-69.
5.
Ibrahim T, Kattan J, Assi T, Chahine G, El Karak F, Nasr F, Ghosn M: Efficacy of a silicon based continuous scalp cooling system with thermostat on chemotherapy induced alopecia. J Palliat Care Med 2015;5:209.
6.
Assi T, Kattan J, Rassy EE, Tabchi S, Chebib R, Moussa T, Hanna C, El Karak F, Farhat F, Ghosn M: Efficacy and safety of everolimus in hormone receptor positive breast cancer in a developing country: real-life single institutional experience. J Can Res Ther 2017;published online ahead of print. www.cancerjournal.net/preprintarticle.asp?id=183552;type=0.
7.
Fraser J, Stelle N, Al Zaman A, Yule A: Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group. Eur J Cancer 2011;47:215-220.
© 2018 S. Karger GmbH, Freiburg
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.